Drugs / Abexinostat
Abexinostat
also known as
PCI 24781 · Abexinostat hcl · ABEXINOSTAT HYDROCHLORIDE · CRA 024781 HYDROCHLORIDE · CRA 24781 HYDROCHLORIDE · CRA-024781 · CRA-024781 HCL · CRA-024781-01 · +6 more
Trials 15
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-09-26 | Xynomic Pharmaceuticals, Inc. | Results Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors xynomicpharma.com ↗
Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead candidate abexinostat, an orally dosed, hydroxamic acid-based small molecule histone deacetylase (“HDAC”) inhibitor , in combination with Keytruda®, for the treatment of multiple solid tumors. |
| 2019-09-26 | Xynomic Pharmaceuticals, Inc. | Regulatory Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma xynomicpharma.com ↗
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma |
| 2019-09-01 | Xynomic Pharmaceuticals, Inc. | Results Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors xynomicpharma.com ↗
In the two dose levels tested (abexinostat 30 mg/m2 and 45 mg/m2 on days 1-4, 8-11 in combination with pembrolizumab 200 mg IV on day 1), there were no dose-limiting toxicities. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-09-26 | Xynomic Pharmaceuticals, Inc. | Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors xynomicpharma.com ↗ |
| 2019-09-26 | Xynomic Pharmaceuticals, Inc. | Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma xynomicpharma.com ↗ |
| 2019-09-01 | Xynomic Pharmaceuticals, Inc. | Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors xynomicpharma.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abexinostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03590054 ↗ |
| Known as | Abexinostat hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | ABEXINOSTAT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | CRA 024781 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | CRA 24781 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | CRA-024781 | “CRA-024781 is a novel, broad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is...” PMID 16731764 ↗ May 2006 |
| Known as | CRA-024781 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | CRA-024781-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | CRA-24781 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473577 ↗ |
| Known as | PCI 24781 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05698524 ↗ |
| Known as | PCI 24781 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | PCI-24781-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | PZP115891 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01543763 ↗ |
| Known as | S-78454 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Known as | S-78454-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗ |
| Action | Inhibit | “Pan-histone Deacetylase (HDAC) Inhibitor” NCT01149668 ↗ |
| Modality | Small molecule | — CHEMBL2103863 ↗ |
| Route | Oral | “PCI-24781 orally at doses starting at 30 mg/m2” NCT00562224 ↗ |